CA2879814A1

CA2879814A1 - Antibodies or fusion proteins multimerized via cysteine mutation and a mu tailpiece

Antibodies or fusion proteins multimerized via cysteine mutation and a mu tailpiece Download PDF

Info

Publication number: CA2879814A1
Authority: CA; Canada
Prior art keywords: antibody; fusion protein; antibodies; protein; region
Prior art date: 2012-08-02
Legal status : Pending

Application number

CA2879814A

Other languages

English (en)

French (fr)

Inventor

Naoya Tsurushita

J. Yun Tso

Current Assignee

JN Biosciences LLC

Original Assignee

JN Biosciences LLC

Priority date

2012-08-02

Filing date

2013-07-31

Publication date

2014-02-06

2013-07-31 Application filed by JN Biosciences LLC filed Critical JN Biosciences LLC

2014-02-06 Publication of CA2879814A1 publication Critical patent/CA2879814A1/en

Status Pending legal-status Critical Current

Links

108020001507 fusion proteins Proteins 0.000 title claims abstract description 204
102000037865 fusion proteins Human genes 0.000 title claims abstract description 203
235000018417 cysteine Nutrition 0.000 title claims abstract description 44
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 title claims abstract description 25
230000035772 mutation Effects 0.000 title abstract description 17
108090000623 proteins and genes Proteins 0.000 claims abstract description 92
102000004169 proteins and genes Human genes 0.000 claims abstract description 56
235000018102 proteins Nutrition 0.000 claims abstract description 52
230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims abstract description 29
101710120037 Toxin CcdB Proteins 0.000 claims abstract description 24
230000014207 opsonization Effects 0.000 claims abstract description 18
241000282414 Homo sapiens Species 0.000 claims description 148
125000003275 alpha amino acid group Chemical group 0.000 claims description 103
102000005962 receptors Human genes 0.000 claims description 34
108020003175 receptors Proteins 0.000 claims description 34
238000000034 method Methods 0.000 claims description 31
108010076504 Protein Sorting Signals Proteins 0.000 claims description 29
108090000765 processed proteins & peptides Proteins 0.000 claims description 28
206010028980 Neoplasm Diseases 0.000 claims description 27
230000006907 apoptotic process Effects 0.000 claims description 23
201000011510 cancer Diseases 0.000 claims description 22
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 22
230000006334 disulfide bridging Effects 0.000 claims description 22
102000004196 processed proteins & peptides Human genes 0.000 claims description 22
229920001184 polypeptide Polymers 0.000 claims description 21
239000013598 vector Substances 0.000 claims description 19
125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 claims description 18
101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims description 9
102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims description 9
101150013553 CD40 gene Proteins 0.000 claims description 8
108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims description 8
102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 8
102000003298 tumor necrosis factor receptor Human genes 0.000 claims description 8
208000026278 immune system disease Diseases 0.000 claims description 7
108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 6
102100040247 Tumor necrosis factor Human genes 0.000 claims description 6
239000008194 pharmaceutical composition Substances 0.000 claims description 6
102100027207 CD27 antigen Human genes 0.000 claims description 5
102000009058 Death Domain Receptors Human genes 0.000 claims description 5
108010049207 Death Domain Receptors Proteins 0.000 claims description 5
101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 5
101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims description 5
102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims description 5
238000004113 cell culture Methods 0.000 claims description 5
101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims description 4
102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims description 4
231100000433 cytotoxic Toxicity 0.000 claims description 4
230000001472 cytotoxic effect Effects 0.000 claims description 4
231100000331 toxic Toxicity 0.000 claims description 4
230000002588 toxic effect Effects 0.000 claims description 4
102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims description 3
108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims description 3
102000019223 Interleukin-1 receptor Human genes 0.000 claims description 3
108050006617 Interleukin-1 receptor Proteins 0.000 claims description 3
108010084313 CD58 Antigens Proteins 0.000 claims description 2
102000046283 TNF-Related Apoptosis-Inducing Ligand Human genes 0.000 claims description 2
108700012411 TNFSF10 Proteins 0.000 claims description 2
101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 1
102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 1
230000027455 binding Effects 0.000 abstract description 85
239000000427 antigen Substances 0.000 abstract description 58
102000036639 antigens Human genes 0.000 abstract description 58
108091007433 antigens Proteins 0.000 abstract description 58
102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 abstract description 24
239000012636 effector Substances 0.000 abstract description 24
101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 abstract description 23
230000006870 function Effects 0.000 abstract description 20
230000001419 dependent effect Effects 0.000 abstract description 13
230000009870 specific binding Effects 0.000 abstract description 12
238000000746 purification Methods 0.000 abstract description 11
238000001727 in vivo Methods 0.000 abstract description 2
210000004027 cell Anatomy 0.000 description 153
238000006467 substitution reaction Methods 0.000 description 48
235000001014 amino acid Nutrition 0.000 description 43
239000000178 monomer Substances 0.000 description 29
238000011282 treatment Methods 0.000 description 26
241000699666 Mus <mouse, genus> Species 0.000 description 25
239000013604 expression vector Substances 0.000 description 24
230000004540 complement-dependent cytotoxicity Effects 0.000 description 22
150000001413 amino acids Chemical class 0.000 description 20
230000000875 corresponding effect Effects 0.000 description 20
102100040113 Tumor necrosis factor receptor superfamily member 10A Human genes 0.000 description 19
101000610605 Homo sapiens Tumor necrosis factor receptor superfamily member 10A Proteins 0.000 description 18
239000012634 fragment Substances 0.000 description 16
108020004414 DNA Proteins 0.000 description 15
-1 0X40 Proteins 0.000 description 14
239000003446 ligand Substances 0.000 description 14
238000002965 ELISA Methods 0.000 description 13
102000002259 TNF-Related Apoptosis-Inducing Ligand Receptors Human genes 0.000 description 13
239000012228 culture supernatant Substances 0.000 description 13
208000035475 disorder Diseases 0.000 description 13
238000004132 cross linking Methods 0.000 description 12
150000001945 cysteines Chemical class 0.000 description 12
108010000449 TNF-Related Apoptosis-Inducing Ligand Receptors Proteins 0.000 description 11
239000002953 phosphate buffered saline Substances 0.000 description 11
NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 10
238000002835 absorbance Methods 0.000 description 10
230000000694 effects Effects 0.000 description 10
238000010828 elution Methods 0.000 description 10
238000002523 gelfiltration Methods 0.000 description 10
238000012360 testing method Methods 0.000 description 10
239000012091 fetal bovine serum Substances 0.000 description 9
238000004519 manufacturing process Methods 0.000 description 9
230000001404 mediated effect Effects 0.000 description 9
239000000203 mixture Substances 0.000 description 9
230000015572 biosynthetic process Effects 0.000 description 8
201000010099 disease Diseases 0.000 description 8
210000000987 immune system Anatomy 0.000 description 8
230000007246 mechanism Effects 0.000 description 8
230000001225 therapeutic effect Effects 0.000 description 8
241000699670 Mus sp. Species 0.000 description 7
206010035226 Plasma cell myeloma Diseases 0.000 description 7
239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 7
241000700605 Viruses Species 0.000 description 7
230000004913 activation Effects 0.000 description 7
GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 7
229960001467 bortezomib Drugs 0.000 description 7
230000003833 cell viability Effects 0.000 description 7
230000003993 interaction Effects 0.000 description 7
231100000167 toxic agent Toxicity 0.000 description 7
239000003440 toxic substance Substances 0.000 description 7
102100032937 CD40 ligand Human genes 0.000 description 6
241000282412 Homo Species 0.000 description 6
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 6
210000001744 T-lymphocyte Anatomy 0.000 description 6
239000000872 buffer Substances 0.000 description 6
230000012010 growth Effects 0.000 description 6
210000004408 hybridoma Anatomy 0.000 description 6
210000002865 immune cell Anatomy 0.000 description 6
230000028993 immune response Effects 0.000 description 6
244000052769 pathogen Species 0.000 description 6
230000004044 response Effects 0.000 description 6
229940124293 CD30 monoclonal antibody Drugs 0.000 description 5
241000701022 Cytomegalovirus Species 0.000 description 5
101000610604 Homo sapiens Tumor necrosis factor receptor superfamily member 10B Proteins 0.000 description 5
230000001154 acute effect Effects 0.000 description 5
238000001042 affinity chromatography Methods 0.000 description 5
238000011091 antibody purification Methods 0.000 description 5
230000030833 cell death Effects 0.000 description 5
239000003153 chemical reaction reagent Substances 0.000 description 5
230000004087 circulation Effects 0.000 description 5
230000000295 complement effect Effects 0.000 description 5
230000000139 costimulatory effect Effects 0.000 description 5
238000002474 experimental method Methods 0.000 description 5
238000011534 incubation Methods 0.000 description 5
208000015181 infectious disease Diseases 0.000 description 5
201000000050 myeloid neoplasm Diseases 0.000 description 5
108020004707 nucleic acids Proteins 0.000 description 5
102000039446 nucleic acids Human genes 0.000 description 5
150000007523 nucleic acids Chemical class 0.000 description 5
230000001717 pathogenic effect Effects 0.000 description 5
239000013612 plasmid Substances 0.000 description 5
230000019491 signal transduction Effects 0.000 description 5
238000013518 transcription Methods 0.000 description 5
230000035897 transcription Effects 0.000 description 5
239000011534 wash buffer Substances 0.000 description 5
238000005406 washing Methods 0.000 description 5
208000023275 Autoimmune disease Diseases 0.000 description 4
102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 4
241000283707 Capra Species 0.000 description 4
108091026890 Coding region Proteins 0.000 description 4
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 4
101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 4
101000840258 Homo sapiens Immunoglobulin J chain Proteins 0.000 description 4
102100029571 Immunoglobulin J chain Human genes 0.000 description 4
102000018697 Membrane Proteins Human genes 0.000 description 4
108010052285 Membrane Proteins Proteins 0.000 description 4
108700026244 Open Reading Frames Proteins 0.000 description 4
239000000556 agonist Substances 0.000 description 4
125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 4
238000010171 animal model Methods 0.000 description 4
210000000612 antigen-presenting cell Anatomy 0.000 description 4
238000003556 assay Methods 0.000 description 4
230000001580 bacterial effect Effects 0.000 description 4
210000004899 c-terminal region Anatomy 0.000 description 4
235000014633 carbohydrates Nutrition 0.000 description 4
150000001720 carbohydrates Chemical class 0.000 description 4
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
230000001413 cellular effect Effects 0.000 description 4
210000000349 chromosome Anatomy 0.000 description 4
238000012217 deletion Methods 0.000 description 4
230000037430 deletion Effects 0.000 description 4
239000003814 drug Substances 0.000 description 4
238000000338 in vitro Methods 0.000 description 4
230000001939 inductive effect Effects 0.000 description 4
238000001990 intravenous administration Methods 0.000 description 4
229940126619 mouse monoclonal antibody Drugs 0.000 description 4
210000000440 neutrophil Anatomy 0.000 description 4
238000002823 phage display Methods 0.000 description 4
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
230000008488 polyadenylation Effects 0.000 description 4
230000000069 prophylactic effect Effects 0.000 description 4
RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 4
238000011160 research Methods 0.000 description 4
230000000717 retained effect Effects 0.000 description 4
241000894007 species Species 0.000 description 4
210000001519 tissue Anatomy 0.000 description 4
230000035899 viability Effects 0.000 description 4
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 3
102100024217 CAMPATH-1 antigen Human genes 0.000 description 3
102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 3
108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 3
108010065524 CD52 Antigen Proteins 0.000 description 3
208000017667 Chronic Disease Diseases 0.000 description 3
108010071942 Colony-Stimulating Factors Proteins 0.000 description 3
101150064015 FAS gene Proteins 0.000 description 3
102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 3
101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 3
206010025323 Lymphomas Diseases 0.000 description 3
101710160107 Outer membrane protein A Proteins 0.000 description 3
229920001213 Polysorbate 20 Polymers 0.000 description 3
229920002684 Sepharose Polymers 0.000 description 3
108091007178 TNFRSF10A Proteins 0.000 description 3
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 3
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 3
230000009798 acute exacerbation Effects 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
230000008901 benefit Effects 0.000 description 3
230000000903 blocking effect Effects 0.000 description 3
230000015556 catabolic process Effects 0.000 description 3
230000010261 cell growth Effects 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
239000012829 chemotherapy agent Substances 0.000 description 3
238000006731 degradation reaction Methods 0.000 description 3
238000005516 engineering process Methods 0.000 description 3
239000003623 enhancer Substances 0.000 description 3
230000004927 fusion Effects 0.000 description 3
102000053594 human TNFRSF10B Human genes 0.000 description 3
230000016784 immunoglobulin production Effects 0.000 description 3
230000003834 intracellular effect Effects 0.000 description 3
230000031146 intracellular signal transduction Effects 0.000 description 3
210000004185 liver Anatomy 0.000 description 3
210000003712 lysosome Anatomy 0.000 description 3
230000001868 lysosomic effect Effects 0.000 description 3
210000002540 macrophage Anatomy 0.000 description 3
230000014759 maintenance of location Effects 0.000 description 3
230000003211 malignant effect Effects 0.000 description 3
239000002609 medium Substances 0.000 description 3
210000001616 monocyte Anatomy 0.000 description 3
210000000822 natural killer cell Anatomy 0.000 description 3
239000002773 nucleotide Substances 0.000 description 3
125000003729 nucleotide group Chemical group 0.000 description 3
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
238000012552 review Methods 0.000 description 3
210000002966 serum Anatomy 0.000 description 3
210000003491 skin Anatomy 0.000 description 3
239000000243 solution Substances 0.000 description 3
239000002904 solvent Substances 0.000 description 3
125000006850 spacer group Chemical group 0.000 description 3
238000003153 stable transfection Methods 0.000 description 3
238000010561 standard procedure Methods 0.000 description 3
238000007920 subcutaneous administration Methods 0.000 description 3
230000004083 survival effect Effects 0.000 description 3
230000009885 systemic effect Effects 0.000 description 3
230000001960 triggered effect Effects 0.000 description 3
230000003442 weekly effect Effects 0.000 description 3
KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
102100038080 B-cell receptor CD22 Human genes 0.000 description 2
241000894006 Bacteria Species 0.000 description 2
208000035143 Bacterial infection Diseases 0.000 description 2
108010029697 CD40 Ligand Proteins 0.000 description 2
208000015943 Coeliac disease Diseases 0.000 description 2
208000035473 Communicable disease Diseases 0.000 description 2
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
102000004127 Cytokines Human genes 0.000 description 2
108090000695 Cytokines Proteins 0.000 description 2
102000053602 DNA Human genes 0.000 description 2
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
102000003886 Glycoproteins Human genes 0.000 description 2
108090000288 Glycoproteins Proteins 0.000 description 2
208000017604 Hodgkin disease Diseases 0.000 description 2
101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 2
101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 2
101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 2
101001133056 Homo sapiens Mucin-1 Proteins 0.000 description 2
101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 2
101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 2
101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 2
206010020751 Hypersensitivity Diseases 0.000 description 2
108060003951 Immunoglobulin Proteins 0.000 description 2
108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
108700005091 Immunoglobulin Genes Proteins 0.000 description 2
102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 2
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
102100034256 Mucin-1 Human genes 0.000 description 2
208000034578 Multiple myelomas Diseases 0.000 description 2
102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 2
108091028043 Nucleic acid sequence Proteins 0.000 description 2
201000004681 Psoriasis Diseases 0.000 description 2
239000012980 RPMI-1640 medium Substances 0.000 description 2
102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 2
PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 2
101001060868 Strawberry mild yellow edge-associated virus Helicase Proteins 0.000 description 2
102100025237 T-cell surface antigen CD2 Human genes 0.000 description 2
102100040112 Tumor necrosis factor receptor superfamily member 10B Human genes 0.000 description 2
102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 description 2
206010046851 Uveitis Diseases 0.000 description 2
108091008605 VEGF receptors Proteins 0.000 description 2
102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 2
208000036142 Viral infection Diseases 0.000 description 2
230000009471 action Effects 0.000 description 2
229960002964 adalimumab Drugs 0.000 description 2
230000007815 allergy Effects 0.000 description 2
230000000735 allogeneic effect Effects 0.000 description 2
230000004075 alteration Effects 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
230000000340 anti-metabolite Effects 0.000 description 2
229940088710 antibiotic agent Drugs 0.000 description 2
230000005888 antibody-dependent cellular phagocytosis Effects 0.000 description 2
229940100197 antimetabolite Drugs 0.000 description 2
239000002256 antimetabolite Substances 0.000 description 2
OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 2
VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 2
210000003719 b-lymphocyte Anatomy 0.000 description 2
208000022362 bacterial infectious disease Diseases 0.000 description 2
229960000397 bevacizumab Drugs 0.000 description 2
230000001588 bifunctional effect Effects 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
230000037396 body weight Effects 0.000 description 2
238000006664 bond formation reaction Methods 0.000 description 2
230000001925 catabolic effect Effects 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
229960005395 cetuximab Drugs 0.000 description 2
238000002512 chemotherapy Methods 0.000 description 2
210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 2
230000001684 chronic effect Effects 0.000 description 2
239000002131 composite material Substances 0.000 description 2
238000010276 construction Methods 0.000 description 2
239000000356 contaminant Substances 0.000 description 2
229960004397 cyclophosphamide Drugs 0.000 description 2
230000006378 damage Effects 0.000 description 2
230000034994 death Effects 0.000 description 2
210000004443 dendritic cell Anatomy 0.000 description 2
238000011161 development Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
230000004069 differentiation Effects 0.000 description 2
239000000539 dimer Substances 0.000 description 2
238000006471 dimerization reaction Methods 0.000 description 2
238000004520 electroporation Methods 0.000 description 2
102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 2
108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 2
238000001914 filtration Methods 0.000 description 2
230000002068 genetic effect Effects 0.000 description 2
230000036541 health Effects 0.000 description 2
210000002216 heart Anatomy 0.000 description 2
239000000833 heterodimer Substances 0.000 description 2
238000011577 humanized mouse model Methods 0.000 description 2
230000001900 immune effect Effects 0.000 description 2
102000018358 immunoglobulin Human genes 0.000 description 2
230000006882 induction of apoptosis Effects 0.000 description 2
230000002458 infectious effect Effects 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
230000000977 initiatory effect Effects 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000002347 injection Methods 0.000 description 2
230000002452 interceptive effect Effects 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
230000002147 killing effect Effects 0.000 description 2
210000004072 lung Anatomy 0.000 description 2
210000004962 mammalian cell Anatomy 0.000 description 2
230000004660 morphological change Effects 0.000 description 2
238000002703 mutagenesis Methods 0.000 description 2
231100000350 mutagenesis Toxicity 0.000 description 2
YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 2
229960005027 natalizumab Drugs 0.000 description 2
108010068617 neonatal Fc receptor Proteins 0.000 description 2
230000007935 neutral effect Effects 0.000 description 2
230000009871 nonspecific binding Effects 0.000 description 2
235000006408 oxalic acid Nutrition 0.000 description 2
229960001972 panitumumab Drugs 0.000 description 2
230000036961 partial effect Effects 0.000 description 2
230000008884 pinocytosis Effects 0.000 description 2
150000003057 platinum Chemical class 0.000 description 2
229910052697 platinum Inorganic materials 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
229950010131 puromycin Drugs 0.000 description 2
230000010076 replication Effects 0.000 description 2
238000003118 sandwich ELISA Methods 0.000 description 2
230000028327 secretion Effects 0.000 description 2
235000020183 skimmed milk Nutrition 0.000 description 2
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
239000000758 substrate Substances 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
238000001890 transfection Methods 0.000 description 2
238000011830 transgenic mouse model Methods 0.000 description 2
229960000575 trastuzumab Drugs 0.000 description 2
239000013638 trimer Substances 0.000 description 2
210000004881 tumor cell Anatomy 0.000 description 2
241000701161 unidentified adenovirus Species 0.000 description 2
230000003612 virological effect Effects 0.000 description 2
238000002424 x-ray crystallography Methods 0.000 description 2
HKZAAJSTFUZYTO-LURJTMIESA-N (2s)-2-[[2-[[2-[[2-[(2-aminoacetyl)amino]acetyl]amino]acetyl]amino]acetyl]amino]-3-hydroxypropanoic acid Chemical compound NCC(=O)NCC(=O)NCC(=O)NCC(=O)N[C@@H](CO)C(O)=O HKZAAJSTFUZYTO-LURJTMIESA-N 0.000 description 1
VILFTWLXLYIEMV-UHFFFAOYSA-N 1,5-difluoro-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC([N+]([O-])=O)=C(F)C=C1F VILFTWLXLYIEMV-UHFFFAOYSA-N 0.000 description 1
YBBNVCVOACOHIG-UHFFFAOYSA-N 2,2-diamino-1,4-bis(4-azidophenyl)-3-butylbutane-1,4-dione Chemical compound C=1C=C(N=[N+]=[N-])C=CC=1C(=O)C(N)(N)C(CCCC)C(=O)C1=CC=C(N=[N+]=[N-])C=C1 YBBNVCVOACOHIG-UHFFFAOYSA-N 0.000 description 1
GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 1
102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 1
108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 1
MJZJYWCQPMNPRM-UHFFFAOYSA-N 6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,6-dihydro-1,3,5-triazine-2,4-diamine Chemical compound CC1(C)N=C(N)N=C(N)N1OCCCOC1=CC(Cl)=C(Cl)C=C1Cl MJZJYWCQPMNPRM-UHFFFAOYSA-N 0.000 description 1
STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
102000014022 A Kinase Anchor Proteins Human genes 0.000 description 1
108010011122 A Kinase Anchor Proteins Proteins 0.000 description 1
241000251468 Actinopterygii Species 0.000 description 1
108010054404 Adenylyl-sulfate kinase Proteins 0.000 description 1
108060003345 Adrenergic Receptor Proteins 0.000 description 1
102000017910 Adrenergic receptor Human genes 0.000 description 1
102100026882 Alpha-synuclein Human genes 0.000 description 1
102000009091 Amyloidogenic Proteins Human genes 0.000 description 1
108010048112 Amyloidogenic Proteins Proteins 0.000 description 1
102000008873 Angiotensin II receptor Human genes 0.000 description 1
108050000824 Angiotensin II receptor Proteins 0.000 description 1
208000031873 Animal Disease Models Diseases 0.000 description 1
108010032595 Antibody Binding Sites Proteins 0.000 description 1
208000006400 Arbovirus Encephalitis Diseases 0.000 description 1
241000228212 Aspergillus Species 0.000 description 1
241000304886 Bacilli Species 0.000 description 1
241000193738 Bacillus anthracis Species 0.000 description 1
208000003508 Botulism Diseases 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
241000701822 Bovine papillomavirus Species 0.000 description 1
208000011691 Burkitt lymphomas Diseases 0.000 description 1
229940123189 CD40 agonist Drugs 0.000 description 1
102100032912 CD44 antigen Human genes 0.000 description 1
102100025221 CD70 antigen Human genes 0.000 description 1
108010021064 CTLA-4 Antigen Proteins 0.000 description 1
229940045513 CTLA4 antagonist Drugs 0.000 description 1
101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
241000222120 Candida <Saccharomycetales> Species 0.000 description 1
101710132601 Capsid protein Proteins 0.000 description 1
102000014914 Carrier Proteins Human genes 0.000 description 1
102000000844 Cell Surface Receptors Human genes 0.000 description 1
108010001857 Cell Surface Receptors Proteins 0.000 description 1
238000003734 CellTiter-Glo Luminescent Cell Viability Assay Methods 0.000 description 1
108091006146 Channels Proteins 0.000 description 1
241000606161 Chlamydia Species 0.000 description 1
206010008631 Cholera Diseases 0.000 description 1
102000009660 Cholinergic Receptors Human genes 0.000 description 1
108010009685 Cholinergic Receptors Proteins 0.000 description 1
101710094648 Coat protein Proteins 0.000 description 1
108020004705 Codon Proteins 0.000 description 1
206010009900 Colitis ulcerative Diseases 0.000 description 1
206010009944 Colon cancer Diseases 0.000 description 1
108010047041 Complementarity Determining Regions Proteins 0.000 description 1
108091035707 Consensus sequence Proteins 0.000 description 1
241000557626 Corvus corax Species 0.000 description 1
235000005956 Cosmos caudatus Nutrition 0.000 description 1
241000709687 Coxsackievirus Species 0.000 description 1
241000699802 Cricetulus griseus Species 0.000 description 1
208000011231 Crohn disease Diseases 0.000 description 1
241001337994 Cryptococcus <scale insect> Species 0.000 description 1
241000223935 Cryptosporidium Species 0.000 description 1
102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 1
108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 1
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
108010036949 Cyclosporine Proteins 0.000 description 1
UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 1
239000012626 DNA minor groove binder Substances 0.000 description 1
101710088194 Dehydrogenase Proteins 0.000 description 1
241000725619 Dengue virus Species 0.000 description 1
102000015554 Dopamine receptor Human genes 0.000 description 1
108050004812 Dopamine receptor Proteins 0.000 description 1
102000001301 EGF receptor Human genes 0.000 description 1
108060006698 EGF receptor Proteins 0.000 description 1
241001466953 Echovirus Species 0.000 description 1
241000709661 Enterovirus Species 0.000 description 1
241000991587 Enterovirus C Species 0.000 description 1
102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 description 1
108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 1
108010008165 Etanercept Proteins 0.000 description 1
108700024394 Exon Proteins 0.000 description 1
108091008794 FGF receptors Proteins 0.000 description 1
241000710831 Flavivirus Species 0.000 description 1
206010017533 Fungal infection Diseases 0.000 description 1
241000233866 Fungi Species 0.000 description 1
108091006027 G proteins Proteins 0.000 description 1
102000005915 GABA Receptors Human genes 0.000 description 1
108010005551 GABA Receptors Proteins 0.000 description 1
102000030782 GTP binding Human genes 0.000 description 1
108091000058 GTP-Binding Proteins 0.000 description 1
241001663880 Gammaretrovirus Species 0.000 description 1
108700007698 Genetic Terminator Regions Proteins 0.000 description 1
241000224467 Giardia intestinalis Species 0.000 description 1
102000018899 Glutamate Receptors Human genes 0.000 description 1
108010027915 Glutamate Receptors Proteins 0.000 description 1
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
108010009202 Growth Factor Receptors Proteins 0.000 description 1
102000009465 Growth Factor Receptors Human genes 0.000 description 1
108010078321 Guanylate Cyclase Proteins 0.000 description 1
102000014469 Guanylate cyclase Human genes 0.000 description 1
102000006354 HLA-DR Antigens Human genes 0.000 description 1
108010058597 HLA-DR Antigens Proteins 0.000 description 1
239000012981 Hank's balanced salt solution Substances 0.000 description 1
208000002250 Hematologic Neoplasms Diseases 0.000 description 1
102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
102100022623 Hepatocyte growth factor receptor Human genes 0.000 description 1
108700019828 Hinge Exons Proteins 0.000 description 1
108010093488 His-His-His-His-His-His Proteins 0.000 description 1
241000228402 Histoplasma Species 0.000 description 1
101100099884 Homo sapiens CD40 gene Proteins 0.000 description 1
101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
101000934356 Homo sapiens CD70 antigen Proteins 0.000 description 1
101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
101000972946 Homo sapiens Hepatocyte growth factor receptor Proteins 0.000 description 1
101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 description 1
101000623901 Homo sapiens Mucin-16 Proteins 0.000 description 1
101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 description 1
101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
241000598436 Human T-cell lymphotropic virus Species 0.000 description 1
241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
241000701024 Human betaherpesvirus 5 Species 0.000 description 1
241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
108010008212 Integrin alpha4beta1 Proteins 0.000 description 1
102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
102000000589 Interleukin-1 Human genes 0.000 description 1
108010002352 Interleukin-1 Proteins 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
108010002616 Interleukin-5 Proteins 0.000 description 1
102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 description 1
108091092195 Intron Proteins 0.000 description 1
102000004310 Ion Channels Human genes 0.000 description 1
108090000862 Ion Channels Proteins 0.000 description 1
241000701460 JC polyomavirus Species 0.000 description 1
241000588748 Klebsiella Species 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
208000006404 Large Granular Lymphocytic Leukemia Diseases 0.000 description 1
241000589248 Legionella Species 0.000 description 1
208000007764 Legionnaires' Disease Diseases 0.000 description 1
206010024238 Leptospirosis Diseases 0.000 description 1
239000012097 Lipofectamine 2000 Substances 0.000 description 1
208000016604 Lyme disease Diseases 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
239000012515 MabSelect SuRe Substances 0.000 description 1
101710125418 Major capsid protein Proteins 0.000 description 1
241000712079 Measles morbillivirus Species 0.000 description 1
102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 1
206010027926 Monoplegia Diseases 0.000 description 1
102100023123 Mucin-16 Human genes 0.000 description 1
241000711386 Mumps virus Species 0.000 description 1
241000699660 Mus musculus Species 0.000 description 1
101100369993 Mus musculus Tnfsf10 gene Proteins 0.000 description 1
102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 1
108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 1
208000031888 Mycoses Diseases 0.000 description 1
125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
238000005481 NMR spectroscopy Methods 0.000 description 1
241000588653 Neisseria Species 0.000 description 1
108010032605 Nerve Growth Factor Receptors Proteins 0.000 description 1
108010040722 Neurokinin-2 Receptors Proteins 0.000 description 1
101710141454 Nucleoprotein Proteins 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
241001631646 Papillomaviridae Species 0.000 description 1
206010057249 Phagocytosis Diseases 0.000 description 1
244000203593 Piper nigrum Species 0.000 description 1
206010035148 Plague Diseases 0.000 description 1
241000224016 Plasmodium Species 0.000 description 1
108700023400 Platelet-activating factor receptors Proteins 0.000 description 1
102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 1
241000233870 Pneumocystis Species 0.000 description 1
102000004257 Potassium Channel Human genes 0.000 description 1
241000288906 Primates Species 0.000 description 1
102000029797 Prion Human genes 0.000 description 1
108091000054 Prion Proteins 0.000 description 1
101710083689 Probable capsid protein Proteins 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
241000588769 Proteus <enterobacteria> Species 0.000 description 1
108010089836 Proto-Oncogene Proteins c-met Proteins 0.000 description 1
102000008022 Proto-Oncogene Proteins c-met Human genes 0.000 description 1
241000125945 Protoparvovirus Species 0.000 description 1
208000010362 Protozoan Infections Diseases 0.000 description 1
241000589516 Pseudomonas Species 0.000 description 1
108020005067 RNA Splice Sites Proteins 0.000 description 1
241000711798 Rabies lyssavirus Species 0.000 description 1
241000700159 Rattus Species 0.000 description 1
241000725643 Respiratory syncytial virus Species 0.000 description 1
241000606651 Rickettsiales Species 0.000 description 1
241000702670 Rotavirus Species 0.000 description 1
241000710799 Rubella virus Species 0.000 description 1
238000011579 SCID mouse model Methods 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
241000607142 Salmonella Species 0.000 description 1
208000034189 Sclerosis Diseases 0.000 description 1
102000003800 Selectins Human genes 0.000 description 1
108090000184 Selectins Proteins 0.000 description 1
241000607720 Serratia Species 0.000 description 1
108010071390 Serum Albumin Proteins 0.000 description 1
102000007562 Serum Albumin Human genes 0.000 description 1
108010003723 Single-Domain Antibodies Proteins 0.000 description 1
102100039024 Sphingosine kinase 1 Human genes 0.000 description 1
241001279361 Stachybotrys Species 0.000 description 1
241000295644 Staphylococcaceae Species 0.000 description 1
241000191967 Staphylococcus aureus Species 0.000 description 1
206010072148 Stiff-Person syndrome Diseases 0.000 description 1
102100037342 Substance-K receptor Human genes 0.000 description 1
230000024932 T cell mediated immunity Effects 0.000 description 1
108091008874 T cell receptors Proteins 0.000 description 1
102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
201000008717 T-cell large granular lymphocyte leukemia Diseases 0.000 description 1
206010042971 T-cell lymphoma Diseases 0.000 description 1
208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
101710165202 T-cell surface antigen CD2 Proteins 0.000 description 1
102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
210000000662 T-lymphocyte subset Anatomy 0.000 description 1
QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
229940123237 Taxane Drugs 0.000 description 1
206010043376 Tetanus Diseases 0.000 description 1
102000036693 Thrombopoietin Human genes 0.000 description 1
108010041111 Thrombopoietin Proteins 0.000 description 1
102000009618 Transforming Growth Factors Human genes 0.000 description 1
108010009583 Transforming Growth Factors Proteins 0.000 description 1
206010052779 Transplant rejections Diseases 0.000 description 1
101000980463 Treponema pallidum (strain Nichols) Chaperonin GroEL Proteins 0.000 description 1
102100033725 Tumor necrosis factor receptor superfamily member 16 Human genes 0.000 description 1
102000008314 Type 1 Melanocortin Receptor Human genes 0.000 description 1
108010021428 Type 1 Melanocortin Receptor Proteins 0.000 description 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
102000014384 Type C Phospholipases Human genes 0.000 description 1
108010079194 Type C Phospholipases Proteins 0.000 description 1
108091005906 Type I transmembrane proteins Proteins 0.000 description 1
201000006704 Ulcerative Colitis Diseases 0.000 description 1
241000700618 Vaccinia virus Species 0.000 description 1
238000005411 Van der Waals force Methods 0.000 description 1
JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
229940122803 Vinca alkaloid Drugs 0.000 description 1
241000101098 Xenotropic MuLV-related virus Species 0.000 description 1
241000607479 Yersinia pestis Species 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
229960003697 abatacept Drugs 0.000 description 1
229960000446 abciximab Drugs 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
239000008351 acetate buffer Substances 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
230000033289 adaptive immune response Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
102000030621 adenylate cyclase Human genes 0.000 description 1
108060000200 adenylate cyclase Proteins 0.000 description 1
238000001261 affinity purification Methods 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
150000001299 aldehydes Chemical class 0.000 description 1
229960002459 alefacept Drugs 0.000 description 1
229960000548 alemtuzumab Drugs 0.000 description 1
229940100198 alkylating agent Drugs 0.000 description 1
239000002168 alkylating agent Substances 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
230000000961 alloantigen Effects 0.000 description 1
108090000185 alpha-Synuclein Proteins 0.000 description 1
230000003942 amyloidogenic effect Effects 0.000 description 1
238000004873 anchoring Methods 0.000 description 1
210000004102 animal cell Anatomy 0.000 description 1
238000011558 animal model by disease Methods 0.000 description 1
229940045799 anthracyclines and related substance Drugs 0.000 description 1
230000003432 anti-folate effect Effects 0.000 description 1
230000000843 anti-fungal effect Effects 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
229940124599 anti-inflammatory drug Drugs 0.000 description 1
230000000884 anti-protozoa Effects 0.000 description 1
230000000840 anti-viral effect Effects 0.000 description 1
229940127074 antifolate Drugs 0.000 description 1
229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 1
239000003443 antiviral agent Substances 0.000 description 1
229940121357 antivirals Drugs 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
229940120638 avastin Drugs 0.000 description 1
229960002170 azathioprine Drugs 0.000 description 1
LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
229960003270 belimumab Drugs 0.000 description 1
108091008324 binding proteins Proteins 0.000 description 1
230000008827 biological function Effects 0.000 description 1
230000008512 biological response Effects 0.000 description 1
229960000074 biopharmaceutical Drugs 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
238000010322 bone marrow transplantation Methods 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
229960002874 briakinumab Drugs 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
229960004562 carboplatin Drugs 0.000 description 1
239000000969 carrier Substances 0.000 description 1
238000000423 cell based assay Methods 0.000 description 1
230000007910 cell fusion Effects 0.000 description 1
230000022534 cell killing Effects 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
210000002421 cell wall Anatomy 0.000 description 1
229960003115 certolizumab pegol Drugs 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
229960004630 chlorambucil Drugs 0.000 description 1
238000011210 chromatographic step Methods 0.000 description 1
229960001265 ciclosporin Drugs 0.000 description 1
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
229960004316 cisplatin Drugs 0.000 description 1
238000003759 clinical diagnosis Methods 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
208000029742 colonic neoplasm Diseases 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
238000012875 competitive assay Methods 0.000 description 1
230000024203 complement activation Effects 0.000 description 1
108010047295 complement receptors Proteins 0.000 description 1
102000006834 complement receptors Human genes 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
239000003246 corticosteroid Substances 0.000 description 1
229960001334 corticosteroids Drugs 0.000 description 1
239000007822 coupling agent Substances 0.000 description 1
230000002089 crippling effect Effects 0.000 description 1
229930182912 cyclosporin Natural products 0.000 description 1
229960000684 cytarabine Drugs 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
230000001085 cytostatic effect Effects 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
231100000135 cytotoxicity Toxicity 0.000 description 1
229960002806 daclizumab Drugs 0.000 description 1
229960000975 daunorubicin Drugs 0.000 description 1
STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
230000006735 deficit Effects 0.000 description 1
230000001934 delay Effects 0.000 description 1
230000008021 deposition Effects 0.000 description 1
230000006866 deterioration Effects 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
125000005442 diisocyanate group Chemical group 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
230000000447 dimerizing effect Effects 0.000 description 1
ZLFRJHOBQVVTOJ-UHFFFAOYSA-N dimethyl hexanediimidate Chemical compound COC(=N)CCCCC(=N)OC ZLFRJHOBQVVTOJ-UHFFFAOYSA-N 0.000 description 1
206010013023 diphtheria Diseases 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
ZWIBGKZDAWNIFC-UHFFFAOYSA-N disuccinimidyl suberate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCCC(=O)ON1C(=O)CCC1=O ZWIBGKZDAWNIFC-UHFFFAOYSA-N 0.000 description 1
239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
230000003828 downregulation Effects 0.000 description 1
229960004679 doxorubicin Drugs 0.000 description 1
229940079593 drug Drugs 0.000 description 1
238000007876 drug discovery Methods 0.000 description 1
229960005501 duocarmycin Drugs 0.000 description 1
229930184221 duocarmycin Natural products 0.000 description 1
229960002224 eculizumab Drugs 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
239000012149 elution buffer Substances 0.000 description 1
230000002357 endometrial effect Effects 0.000 description 1
210000001163 endosome Anatomy 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
238000006911 enzymatic reaction Methods 0.000 description 1
229950009760 epratuzumab Drugs 0.000 description 1
229940082789 erbitux Drugs 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
229960000403 etanercept Drugs 0.000 description 1
229960005420 etoposide Drugs 0.000 description 1
VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 description 1
238000000684 flow cytometry Methods 0.000 description 1
229960000390 fludarabine Drugs 0.000 description 1
GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
150000002222 fluorine compounds Chemical class 0.000 description 1
239000004052 folic acid antagonist Substances 0.000 description 1
238000009472 formulation Methods 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
244000053095 fungal pathogen Species 0.000 description 1
150000002270 gangliosides Chemical class 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
229960000578 gemtuzumab Drugs 0.000 description 1
238000012215 gene cloning Methods 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
210000004602 germ cell Anatomy 0.000 description 1
229940085435 giardia lamblia Drugs 0.000 description 1
102000034238 globular proteins Human genes 0.000 description 1
108091005896 globular proteins Proteins 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
229960001743 golimumab Drugs 0.000 description 1
210000003714 granulocyte Anatomy 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
229940022353 herceptin Drugs 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
210000003630 histaminocyte Anatomy 0.000 description 1
239000005556 hormone Substances 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
229940048921 humira Drugs 0.000 description 1
230000028996 humoral immune response Effects 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
229910052588 hydroxylapatite Inorganic materials 0.000 description 1
229960000908 idarubicin Drugs 0.000 description 1
150000002463 imidates Chemical class 0.000 description 1
239000012642 immune effector Substances 0.000 description 1
230000008629 immune suppression Effects 0.000 description 1
238000003018 immunoassay Methods 0.000 description 1
229940127121 immunoconjugate Drugs 0.000 description 1
229940121354 immunomodulator Drugs 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
229960000598 infliximab Drugs 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
108010044426 integrins Proteins 0.000 description 1
102000006495 integrins Human genes 0.000 description 1
229940079322 interferon Drugs 0.000 description 1
108040006858 interleukin-6 receptor activity proteins Proteins 0.000 description 1
238000001361 intraarterial administration Methods 0.000 description 1
230000004068 intracellular signaling Effects 0.000 description 1
238000007917 intracranial administration Methods 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000007913 intrathecal administration Methods 0.000 description 1
238000005342 ion exchange Methods 0.000 description 1
239000002555 ionophore Substances 0.000 description 1
230000000236 ionophoric effect Effects 0.000 description 1
230000001788 irregular Effects 0.000 description 1
238000005304 joining Methods 0.000 description 1
210000003292 kidney cell Anatomy 0.000 description 1
125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
229940063725 leukeran Drugs 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
210000003141 lower extremity Anatomy 0.000 description 1
206010025135 lupus erythematosus Diseases 0.000 description 1
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
230000002101 lytic effect Effects 0.000 description 1
108010026228 mRNA guanylyltransferase Proteins 0.000 description 1
238000013507 mapping Methods 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
239000012577 media supplement Substances 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
229960001924 melphalan Drugs 0.000 description 1
229960005108 mepolizumab Drugs 0.000 description 1
229960000485 methotrexate Drugs 0.000 description 1
HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
244000000010 microbial pathogen Species 0.000 description 1
244000005700 microbiome Species 0.000 description 1
229960001156 mitoxantrone Drugs 0.000 description 1
KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
238000002156 mixing Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
238000001823 molecular biology technique Methods 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
238000003032 molecular docking Methods 0.000 description 1
230000009456 molecular mechanism Effects 0.000 description 1
206010028417 myasthenia gravis Diseases 0.000 description 1
229960000951 mycophenolic acid Drugs 0.000 description 1
HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
239000013642 negative control Substances 0.000 description 1
230000007524 negative regulation of DNA replication Effects 0.000 description 1
229950010203 nimotuzumab Drugs 0.000 description 1
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
229950005751 ocrelizumab Drugs 0.000 description 1
229960002450 ofatumumab Drugs 0.000 description 1
229960000470 omalizumab Drugs 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
229950002610 otelixizumab Drugs 0.000 description 1
230000002611 ovarian Effects 0.000 description 1
230000000242 pagocytic effect Effects 0.000 description 1
229960000402 palivizumab Drugs 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000037361 pathway Effects 0.000 description 1
XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
230000008782 phagocytosis Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
102000030769 platelet activating factor receptor Human genes 0.000 description 1
201000000317 pneumocystosis Diseases 0.000 description 1
108020001213 potassium channel Proteins 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
230000008569 process Effects 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
238000001742 protein purification Methods 0.000 description 1
108010045647 puromycin N-acetyltransferase Proteins 0.000 description 1
150000003230 pyrimidines Chemical class 0.000 description 1
230000005855 radiation Effects 0.000 description 1
239000002534 radiation-sensitizing agent Substances 0.000 description 1
238000003259 recombinant expression Methods 0.000 description 1
210000000664 rectum Anatomy 0.000 description 1
238000004064 recycling Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
229960003254 reslizumab Drugs 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
229960004641 rituximab Drugs 0.000 description 1
108010017584 romiplostim Proteins 0.000 description 1
229960004262 romiplostim Drugs 0.000 description 1
238000012216 screening Methods 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
WUWDLXZGHZSWQZ-WQLSENKSSA-N semaxanib Chemical compound N1C(C)=CC(C)=C1\C=C/1C2=CC=CC=C2NC\1=O WUWDLXZGHZSWQZ-WQLSENKSSA-N 0.000 description 1
238000000926 separation method Methods 0.000 description 1
125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
239000004017 serum-free culture medium Substances 0.000 description 1
230000007781 signaling event Effects 0.000 description 1
238000002741 site-directed mutagenesis Methods 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
VSIVTUIKYVGDCX-UHFFFAOYSA-M sodium;4-[2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].COC1=CC([N+]([O-])=O)=CC=C1[N+]1=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=NN1C1=CC=C([N+]([O-])=O)C=C1 VSIVTUIKYVGDCX-UHFFFAOYSA-M 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
210000000130 stem cell Anatomy 0.000 description 1
238000002660 stem cell treatment Methods 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000001839 systemic circulation Effects 0.000 description 1
229950010127 teplizumab Drugs 0.000 description 1
125000003831 tetrazolyl group Chemical group 0.000 description 1
125000003396 thiol group Chemical group [H]S* 0.000 description 1
CNHYKKNIIGEXAY-UHFFFAOYSA-N thiolan-2-imine Chemical compound N=C1CCCS1 CNHYKKNIIGEXAY-UHFFFAOYSA-N 0.000 description 1
210000001541 thymus gland Anatomy 0.000 description 1
229960003989 tocilizumab Drugs 0.000 description 1
RUELTTOHQODFPA-UHFFFAOYSA-N toluene 2,6-diisocyanate Chemical compound CC1=C(N=C=O)C=CC=C1N=C=O RUELTTOHQODFPA-UHFFFAOYSA-N 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
229940044693 topoisomerase inhibitor Drugs 0.000 description 1
229960000303 topotecan Drugs 0.000 description 1
UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000002103 transcriptional effect Effects 0.000 description 1
238000005829 trimerization reaction Methods 0.000 description 1
230000005748 tumor development Effects 0.000 description 1
230000005909 tumor killing Effects 0.000 description 1
102000003390 tumor necrosis factor Human genes 0.000 description 1
229940079023 tysabri Drugs 0.000 description 1
241001529453 unidentified herpesvirus Species 0.000 description 1
241000712461 unidentified influenza virus Species 0.000 description 1
230000003827 upregulation Effects 0.000 description 1
210000003932 urinary bladder Anatomy 0.000 description 1
229960003824 ustekinumab Drugs 0.000 description 1
229960004914 vedolizumab Drugs 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
229960003048 vinblastine Drugs 0.000 description 1
JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
229960004528 vincristine Drugs 0.000 description 1
OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
229940075420 xanthine Drugs 0.000 description 1
238000012447 xenograft mouse model Methods 0.000 description 1